Xbrane Biopharma AB Statistics

Total Valuation

STO:XBRANE has a market cap or net worth of SEK 327.12 million. The enterprise value is 394.51 million.

Market Cap	327.12M
Enterprise Value	394.51M

Important Dates

The next estimated earnings date is Monday, March 31, 2025.

Earnings Date	Mar 31, 2025
Ex-Dividend Date	n/a

Share Statistics

STO:XBRANE has 1.53 billion shares outstanding. The number of shares has increased by 4,184.58% in one year.

Current Share Class	n/a
Shares Outstanding	1.53B
Shares Change (YoY)	+4,184.58%
Shares Change (QoQ)	n/a
Owned by Insiders (%)	2.14%
Owned by Institutions (%)	7.55%
Float	1.50B

Valuation Ratios

PE Ratio	n/a
Forward PE	1.61
PS Ratio	1.32
PB Ratio	1.57
P/TBV Ratio	1.57
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-1.48
EV / Sales	1.99
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-2.94

Financial Position

The company has a current ratio of 1.13, with a Debt / Equity ratio of 0.92.

Current Ratio	1.13
Quick Ratio	0.29
Debt / Equity	0.92
Debt / EBITDA	n/a
Debt / FCF	-1.43
Interest Coverage	-6.16

Financial Efficiency

Return on equity (ROE) is -139.53% and return on invested capital (ROIC) is -34.06%.

Return on Equity (ROE)	-139.53%
Return on Assets (ROA)	-18.29%
Return on Invested Capital (ROIC)	-34.06%
Return on Capital Employed (ROCE)	-71.87%
Revenue Per Employee	3.06M
Profits Per Employee	-4.10M
Employee Count	65
Asset Turnover	0.27
Inventory Turnover	0.10

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -22.93% in the last 52 weeks. The beta is 1.14, so STO:XBRANE's price volatility has been higher than the market average.

Beta (5Y)	1.14
52-Week Price Change	-22.93%
50-Day Moving Average	0.17
200-Day Moving Average	0.19
Relative Strength Index (RSI)	57.66
Average Volume (20 Days)	28,173,947

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, STO:XBRANE had revenue of SEK 198.72 million and -266.22 million in losses. Loss per share was -0.22.

Revenue	198.72M
Gross Profit	180.50M
Operating Income	-218.84M
Pretax Income	-253.43M
Net Income	-266.22M
EBITDA	-182.89M
EBIT	-218.84M
Loss Per Share	-0.22

Full Income Statement

Balance Sheet

The company has 124.33 million in cash and 191.72 million in debt, giving a net cash position of -67.39 million or -0.04 per share.

Cash & Cash Equivalents	124.33M
Total Debt	191.72M
Net Cash	-67.39M
Net Cash Per Share	-0.04
Equity (Book Value)	208.54M
Book Value Per Share	0.14
Working Capital	67.96M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -133.73 million and capital expenditures -501,000, giving a free cash flow of -134.23 million.

Operating Cash Flow	-133.73M
Capital Expenditures	-501,000
Free Cash Flow	-134.23M
FCF Per Share	-0.09

Full Cash Flow Statement

Margins

Gross margin is 90.83%, with operating and profit margins of -110.12% and -133.97%.

Gross Margin	90.83%
Operating Margin	-110.12%
Pretax Margin	-127.53%
Profit Margin	-133.97%
EBITDA Margin	-92.03%
EBIT Margin	-110.12%
FCF Margin	n/a

Dividends & Yields

STO:XBRANE does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-4,184.58%
Shareholder Yield	-4,184.58%
Earnings Yield	-81.38%
FCF Yield	-41.03%

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

STO:XBRANE has an Altman Z-Score of -2.82. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-2.82
Piotroski F-Score	n/a